Lionel Berthold Keubou Boukeng

Lionel Berthold Keubou Boukeng

Auto-generated profile, based on publicly available information

Lionel Berthold Keubou Boukeng

Direction for the Fight against Diseases, Epidemics and Pandemics, Ministry of Public Health, Yaounde, Cameroon

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
AAAdidja AMANI
Adidja AMANI
BABrian Ngongheh Ajong
Brian Ngongheh Ajong
LBLionel Berthold Keubou Boukeng
Lionel Berthold Keubou Boukeng
CMChristian Mouangue
Christian Mouangue
FNFlorence Kissougle Nkongo
Florence Kissougle Nkongo
Background: Integrating the principles of humanized care into healthcare systems is critical to promoting optimal well-being throughout the patient care process. In a context of limited resources, improving the quality of care and health services means identifying priority sites to optimize cost-effectiveness. The objective was to measure key indicators of quality and safety of care in health facilities (HFs) and to map priority health districts (HDs) for effective implementation of high-impact interventions in the Centre Region. Methods: We conducted a descriptive cross-sectional analysis using retrospective data from 2018 to 2022 from 32 HDs comprising the Centre Region were extracted in April 2023. Data were retrieved from the national database using DHIS 2 and checked for completeness. The health indicators assessed were those defined in the Cameroon Health Sector Strategy for 2020-2030. Results: The density of the qualified HCWs was 13.7 per 10 000 inhabitants in 2022. The density of doctors in rural areas has fallen sharply over the five-year study period, with a decline of almost 20% by 2020 in favor of urban areas. The Odza HD had the highest inpatient mortality rate over the five-year study period (49%). In rural areas, the Esse HD had the highest mortality rate (32.4%). Esse (18.8%) and Odza (6.7%) HDs had the highest perioperative mortality rates in rural and urban areas, respectively. Most of the urban HDs (5/8=62.5%) had a neonatal mortality rate higher than the regional median (RM=3.1). Half of the rural HDs had a maternal mortality ratio higher than the regional median (RM=118 per 1000 live births). The HDs of Mbandjock (357/1,000) and Mvog-Ada (285/1,000) were the most affected in rural and urban areas respectively. More than two thirds of urban HDs recorded a proportion of free malaria treatment cases below the regional median (14%). Conclusions: Efforts to humanize healthcare in the Centre Region are hindered by persistent disparities in care quality and inconsistent policy implementation. Addressing these challenges requires timely implementation of a National Strategic Plan to Improve the Quality of Healthcare and Service Delivery, emphasizing on capacity building through training and supervision.

28 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
BABrian Ngongheh Ajong
Brian Ngongheh Ajong
AAAdidja AMANI
Adidja AMANI
LBLionel Berthold Keubou Boukeng
Lionel Berthold Keubou Boukeng
CNChristelle Sandrine Ngos
Christelle Sandrine Ngos
CMChristian Mouangue
Christian Mouangue
Background: Cameroon has developed a Health Sector Strategy (HSS) that aims at fostering a healthy and productive human capital. To achieve this objective, key health indicators have been defined to track progress towards the goal. This study was conducted to provide evidence on the current situation and assess progress towards achieving the HSS and other key health indicators in the Centre Region and in Cameroon. Methods: Data were collected in April 2023 through a through a comprehensive review of online documents and databases. They were collected retrospectively till 2022. Data were retrieved from the national database using DHIS2 version 2.40 and checked for completeness. Additional data were gathered from online surveys and reports available including Demographic and Health Survey, Multiple Indicators Cluster Survey, National Statistical Institute report for the Centre Region. Results: At national level, the highest performance was observed in the proportion of HIV-positive pregnant women receiving ART (99%), while the lowest performance was observed in the reduction of the prevalence of chronic malnutrition among children under five, with 63% of the target achieved. In the Centre Region, the national target of reducing the prevalence of chronic malnutrition to 11% was achieved. The lowest performance was observed in the proportion of children under five sleeping under long-lasting insecticidal nets. The density of health facilities was above target at national level (2.3 per 10,000 population) but below target at regional level (1.4 per 10,000 population). Coverage of tracer antigens (Penta 3, BCG) decreased over the five-year study period, falling below the national target of 95% in 2022. However, coverage remained above the national average throughout the study period. Coverage of pregnant women attending four or more antenatal clinics and receiving at least three doses of intermittent preventive treatment (IPT) remained low from 2018 to 2022. Conclusions: Significant progress has been made in strengthening the healthcare system and fostering a healthy, productive workforce. Nevertheless, further efforts are required to prevent malaria transmission, promote antenatal care utilization among pregnant women, and address nutritional insecurity in certain Regions.

13 December 2024 in medRxiv
Verified
Preprint
Open access
PDF file
FCFabrice Zobel Lekeumo Cheuyem
Fabrice Zobel Lekeumo Cheuyem
AAAdidja AMANI
Adidja AMANI
INIyawa Clarisse Alma Nkodo
Iyawa Clarisse Alma Nkodo
LBLionel Bethold Keubou Boukeng
Lionel Bethold Keubou Boukeng
MEMichel Franck EDZAMBA
Michel Franck EDZAMBA
CMChristian Mouangue
Christian Mouangue
Background: The development of effective vaccines was a promising tool for ending the pandemic. However, the success of a vaccination programme depends heavily on achieving significant community acceptance. In Cameroon, numerous studies have investigated the level of acceptance, hesitancy and perception of COVID-19 vaccines, with mixed results. To provide a comprehensive understanding of these parameters, this meta-analysis aimed to estimate the pooled proportion of COVID-19 vaccine acceptance, hesitancy and perception in Cameroon. Methods: A systematic search of online databases, including PubMed, Google Scholar, and ScienceDirect, was conducted to identify relevant research articles. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The extracted data were compiled in a Microsoft Excel spreadsheet and analyzed using R statistical software (version 4.3.3). The pooled proportion of COVID-19 vaccine acceptance, hesitancy, and perception was calculated using random effects meta-analysis. Funnel plots, Egger’s and Begg’s tests were used to assess publication bias. Results: Of the 1243 records identified through the database search, 20 research articles were included in the systematic review and meta-analysis. The random-effects model showed that the that approximately 31.21% (95% CI: 23.49-38.94) of the Cameroonian population was willing to accept the COVID-19 vaccine. More than two-thirds of the population (68.49%; 95% CI: 60.65-76.34) were vaccine hesitant. Half of the participants (51.81%; 95% CI: 42.70-60.93), had a negative perception of the COVID-19 vaccine. The acceptance rate progressed from the first semester of 2021 (27.21%; 95% CI: 10.38-44.05) to the first semester of 2022 (45.56%; 95% CI: 25-66.12). The pooled vaccine acceptance rate was 29.29% (95% CI: 19.86-38.72) for the general population and 39.24% (95% CI: 22.84-55.64) for healthcare workers. The pooled vaccine hesitancy rate was 70.39% (95% CI: 61.30-79.80) for the general population and 57.42 % (95% CI: 4.05-71.80) for healthcare workers Conclusion: Despite progress in vaccine acceptance, targeted interventions are still needed to address vaccine hesitancy in the country. Strategies such as improving access to accurate information, building trust in institutions, and strengthening community engagement are crucial to increasing COVID-19 vaccine uptake.

10 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
DTDavy Roméo Takpando-Le-Grand
Davy Roméo Takpando-Le-Grand
CAChabeja Achangwa
Chabeja Achangwa
LBLionel Berthold Keubou Boukeng
Lionel Berthold Keubou Boukeng
SDSolange Dabou
Solange Dabou
GNGeorges Nguefack-Tsague
Georges Nguefack-Tsague
Background: Mpox remains a critical public health challenge in Central Africa, where endemic circulation of the virulent Clade I virus persists through zoonotic and human-to-human transmission. This systematic review and meta-analysis synthesize 40 years of evidence (1984-2024) to characterize Mpox epidemiology, vaccination gaps and clinical pattern in the Central African Republic (CAR), informing targeted control strategies for this re-emerging threat. Methods: Following PRISMA guidelines, we conducted a comprehensive search of PubMed, Scopus, ScienceDirect, Web of science, Embase, Cochrane Library, and AJOL for studies reporting laboratory-confirmed Mpox cases in CAR. Pooled estimates were calculated using random/fixed-effects models with R Software version 4.4.2 with subgroup analysis conducted for period, region, participants and disease burden. Heterogeneity ( I 2 ) and publication bias (funnel plots, Egger’s and Begg’s tests) were rigorously assessed. The confidence intervals (CIs) were estimated at 95% level of confidence. A p -value ⍰5% was considered statistically significant. Results: Analysis of seven studies (1984-2023) found a pooled severity rate of 60.9% (95%CI: 48.5-77.7), peaking at 77.3% (95%CI: 55.6-90.2) in Health Region 6. Before the global mpox outbreak, the CFR for confirmed cases was 11.54% (95% CI: 6.11-20.71). Eastern Health Regions had a higher CFR of 11.11% (95% CI: 5.08-22.60), while Western Regions reported 0.00% (95% CI: 0.00-100.00). For suspected cases, the CFR was 12.77% (95% CI: 7.39-21.15), slightly declining to 9.09% (95% CI: 0.23-41.28) post-2022. This geographic disparity remained, with Eastern Regions at 10.17% (95% CI: 4.64-20.84) and Western Regions at 5.26% (95% CI: 0.74-29.39). Vaccination uptake in CAR was only 20.00% (95% CI: 10.33-35.17). The clinical profile included fever (91.1% (95%CI: 42.9-99.3)), rash (85.5% (95%CI: 75.7-91.8)), and lymphadenopathy (57.0% (95%CI: 34.3-77.1)). Conclusion: The CAR faces a disproportionate Mpox burden characterized by high severity, elevated mortality, and suboptimal vaccine coverage, particularly in eastern regions. These findings suggest the urgent need for: (1) enhanced surveillance systems with genomic sequencing capacity; (2) prevention of disease lethality through early case detection and appropriate care provision; (3) strengthening vaccine distribution prioritizing high-risk populations; and (4) context-specific interventions, including community education and healthcare worker training, to curb future outbreaks.

11 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
CAChabeja Achangwa
Chabeja Achangwa
LBLionel Berthold Keubou Boukeng
Lionel Berthold Keubou Boukeng
RTRick Tchamani
Rick Tchamani
ACAlapa Junior Nkwate Chefor
Alapa Junior Nkwate Chefor
EBEdmond Martial Lemaire Bodo
Edmond Martial Lemaire Bodo
Background: High-risk human papillomavirus (HR-HPV) infection is the necessary cause of cervical cancer, a leading cause of cancer mortality among women in sub-Saharan Africa. In Cameroon, there is a gap in synthetized evidence on HR-HPV epidemiology, limiting data-driven prevention strategies. This study provides the first comprehensive national synthesis of HR-HPV prevalence, genotype distribution, and HIV co-infection among HPV-infected individuals. Methods: A systematic review and meta-analysis were conducted following PRISMA guidelines and registered in PROSPERO (CRD420261282094). We systematically searched PubMed, Scopus, Web of Science, Embase, Cochrane Library, AJOL and local online publishers. Studies reporting the prevalence of HR-HPV among sexually active individuals were included. Pooled prevalence estimates were calculated using random-effects meta-analysis. Heterogeneity was assessed with I² statistics and explored through subgroup analyses. The methodological quality of included studies was evaluated using the Joanna Briggs Institute (JBI) critical appraisal tools. Results: A total of 33 studies including 18,798 participants were included in this analysis. The overall pooled prevalence of HR-HPV was 28.95% (95% CI: 19.74–40.30; 33 studies; n = 18,798; I 2 = 98.7%), with a notable decline from 53.34% before 2014 to 21.43% in 2021–2023. Prevalence varied substantially across populations, being highest among women with precancerous or cancerous lesions (90.69%; 95% CI: 78.48–96.30) and female sex workers (62.10%; 95% CI: 58.08–66.00) compared to women from the general population (21.09%; 95% CI: 15.16–28.55). Among HPV-positive women, HIV co-infection prevalence was 26.17% (95% CI: 13.48–44.65, 19 studies; n = 3,589; I 2 = 97.9%), with higher rates in hospital-based studies (34.57%) compared to community-based studies (9.18%). Predominant HR-HPV genotypes included HPV16 (28.7%), HPV52 (23.6%), HPV6 6 (22.9%), HPV33 (22.8%), and HPV18 (20.2%). The pooled prevalence of abnormal cervical lesions among HPV-positive women was 35.15% (95% CI: 20.21–53.70; 12 studies; n = 2,186; I 2 = 95.2%), comprising low-grade lesions (34.4%) and high-grade lesions (19.1%). Conclusions: High-risk human papillomavirus infection remains highly prevalent in Cameroon despite encouraging temporal declines. The substantial burden of HIV co-infection and circulation of multiple oncogenic genotypes underscore the need for integrated HPV–HIV prevention strategies, expanded screening, and consideration of broader-coverage vaccines to accelerate progress toward cervical cancer elimination targets.

9 February 2026 in medRxiv
Verified
Preprint
Open access
PDF file
Cheuyem Lekeumo Fabrice ZobelCheuyem Lekeumo Fabrice Zobel
Cheuyem Lekeumo Fabrice Zobel
CAChabeja Achangwa
Chabeja Achangwa
LBLionel Berthold Keubou Boukeng
Lionel Berthold Keubou Boukeng
RTRick Tchamani
Rick Tchamani
JDJessica Davies
Jessica Davies
AMArmel Evouna Mbarga
Armel Evouna Mbarga
Background: Africa continues to have a significant public health problem with mpox, where endemic transmission persists and overlaps with a high burden of other infectious diseases. Although their epidemiology and clinical impact are still poorly understood throughout the continent, coinfections with human immunodeficiency virus (HIV) and varicella-zoster virus (VZV) can affect the clinical picture, severity of the disease, and accuracy of the diagnosis. Methods: Following PRISMA criteria, we registered the protocol in PROSPERO (CRD420251133960) and carried out a methodical review and meta-analysis. Through searches of numerous electronic databases and grey literature up to February 27, 2025, observational studies documenting mpox coinfections with VZV and/or HIV and related clinical symptoms in Africa were searched. Pooled prevalence was calculated using random-effects models. Subgroup analyses and meta-regression were conducted to investigate heterogeneity across WHO regions, countries, study designs, settings and type of participants. Results: A total of 27 studies carried out across African countries were included. The pooled prevalence of VZV–mpox coinfection was 10.23% (95% CI: 2.95–29.93), while HIV–mpox coinfection prevalence was 6.55% (95% CI: 2.36–16.90), both of which had significant heterogeneity. Coinfections were far more prevalent in hospital-based environments than in community-based research. The rash was nearly universal throughout all clades, but the clinical manifestations varied depending on the viral clade, with clades I and Ia linked to more severe systemic symptoms than clade II. Discussions: HIV and VZV coinfections with mpox pose a major yet possibly underestimated burden in Africa and are linked to more severe clinical presentations, particularly in hospital environments. The necessity of including clinical, epidemiological, and genomic data into mpox monitoring systems is emphasized by the observed clinical differences between clades. Improving patient management and outbreak preparedness across the continent requires strengthening diagnostic capacity and routinely screening for coinfections.